The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.
Company Info
| CEO | Mark J. Alles |
| CEO Title | Chief Executive Officer & Director |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Summit, NJ |
| Website | www.celgene.com |
| Years on Fortune 500 List | 6 |
| Employees | 7,132 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $11,229 |
| Profits ($M) | $1,999.2 |
| Assets ($M) | $28,086 |
| Total Stockholder Equity ($M) | $6,599 |
| Market Value — as of March 31, 2017 ($M) | $96,802 |
Profit Ratios
| Profit as % of Revenues | 17.8% |
| Profits as % of Assets | 7.1% |
| Profits as % of Stockholder Equity | 30.3% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 2 |
| EPS % Change (from 2015) | 28.4% |
| EPS % Change (5 year annual rate) | 11.8% |
| EPS % Change (10 year annual rate) | 39.4% |
Total Return
| Total Return to Investors (2016) | -3.3% |
| Total Return to Investors (5 year, annualized) | 27.9% |
| Total Return to Investors (10 year, annualized) | 14.9% |
